Revisor Wealth Management LLC Acquires 4,430 Shares of Becton, Dickinson and Company $BDX

Revisor Wealth Management LLC grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 65.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,167 shares of the medical instruments supplier’s stock after purchasing an additional 4,430 shares during the period. Revisor Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $2,244,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of BDX. Wellington Management Group LLP increased its holdings in shares of Becton, Dickinson and Company by 9,056.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock worth $979,290,000 after purchasing an additional 5,174,944 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in shares of Becton, Dickinson and Company by 13.8% in the 3rd quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier’s stock worth $1,870,653,000 after purchasing an additional 1,208,218 shares in the last quarter. Veritas Asset Management LLP increased its holdings in shares of Becton, Dickinson and Company by 40.6% in the 3rd quarter. Veritas Asset Management LLP now owns 2,954,898 shares of the medical instruments supplier’s stock worth $553,068,000 after purchasing an additional 852,854 shares in the last quarter. Rakuten Investment Management Inc. bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth $152,931,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Becton, Dickinson and Company by 7.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 9,150,584 shares of the medical instruments supplier’s stock worth $1,712,715,000 after purchasing an additional 636,138 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on BDX shares. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Wells Fargo & Company dropped their price target on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 10th. Argus dropped their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Finally, The Goldman Sachs Group started coverage on Becton, Dickinson and Company in a research note on Friday, April 10th. They issued a “neutral” rating and a $167.00 price target on the stock. Six research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $189.08.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $158.32 on Monday. The company has a market cap of $45.08 billion, a P/E ratio of 25.83, a price-to-earnings-growth ratio of 11.28 and a beta of 0.29. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The stock’s fifty day moving average price is $165.88 and its 200-day moving average price is $184.32.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $4.49 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period last year, the business posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th were given a dividend of $1.05 per share. The ex-dividend date was Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.7%. Becton, Dickinson and Company’s payout ratio is 68.52%.

Becton, Dickinson and Company declared that its board has authorized a stock buyback plan on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In related news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 1,103 shares of company stock worth $202,870 in the last quarter. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.